New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 12, 2013
11:01 EDTA, LLY, PFEAgilent's Dako to collaborate with Pfizer on companion diagnostics
Dako, an Agilent Technologies (A) company, announced today it has entered into a collaboration agreement with Pfizer (PFE) in the field of companion diagnostics. The agreement constitutes a legal framework for various collaboration projects between the two companies, covering research, development and commercialization as well as advisory services. Financial terms of the agreement were not disclosed. This news follows an earlier announcement from Dako introducing a master framework agreement between Dako and Eli Lilly (LLY).
News For A;PFE;LLY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 3, 2015
09:01 EDTPFEPfizer completes acquisition of Hospira
Subscribe for More Information
September 2, 2015
16:27 EDTAAgilent will will no longer include orders in financial reporting
Agilent Technologies announced it will no longer report orders in its periodic filings with the SEC or its quarterly earnings press releases, effective immediately. This change reflects feedback from several of the company's largest shareholders, and was also driven by the fact that Agilent was the only company among its peers to report orders. The other financial metrics included in the company's reporting provide comprehensive detail about Agilent's performance.
September 1, 2015
18:19 EDTPFEJudge says inclined to proceed with Pfizer lawsuit, WSJ reports
Subscribe for More Information
August 31, 2015
09:11 EDTPFEEuropean Society of Cardiology
Subscribe for More Information
August 27, 2015
17:38 EDTPFES&P announces changes to S&P 500 index
Subscribe for More Information
10:32 EDTLLYFDA approvals Synjardy tablets for adults with Type 2 diabetes
Subscribe for More Information
07:24 EDTPFEPfizer shares even more compelling after recent weakness, says Piper Jaffray
Subscribe for More Information
06:55 EDTPFEHospira sees merger closing on or about September 3
Hospira (HSP) said in a regulatory filing that on August 21, Hospira and Pfizer (PFE) received clearance from the U.S. FTC, relating to the pending merger of Hospira with Perkins Holding Company, a wholly-owned subsidiary of Pfizer. All required regulatory approvals have now been secured, though the merger remains conditioned upon the expiration of a post-clearance waiting period in one foreign jurisdiction. Hospira expects the merger to close on or about September 3.
05:20 EDTLLYEli Lilly, Adocia initiate new Phase 1b study of BioChaperone Lispro
Subscribe for More Information
August 26, 2015
11:01 EDTAAgilent partners with Weill Cornell Medical College for ALS research
Subscribe for More Information
07:32 EDTPFEPfizer launches Phase 3 trial of targeted therapy for breast cancer patients
Subscribe for More Information
06:16 EDTPFEAlvogen to acquire product portfolio from Pfizer for US market
Subscribe for More Information
August 25, 2015
17:11 EDTLLYU.S. District Court rules in Eli Lilly's favor on Alimta vitamin regimen patent
Subscribe for More Information
14:16 EDTPFEMylan launches generic version of Pfizer's Zosyn Injection
Mylan (MYL) announced the U.S. launch of Piperacillin and Tazobactam for Injection USP, 3.375g Single-dose Vials, which is the generic version of Pfizer's (PFE) Zosyn Injection. This product is a combination penicillin-class antibacterial and beta-lactamase inhibitor indicated for the treatment of patients with moderate to severe infections caused by susceptible isolates of certain bacteria. Piperacillin and Tazobactam for Injection USP, 3.375g Single-dose Vials had U.S. sales of approximately $72.1M for the 12 months ending June 30, 2015, according to IMS Health. Mylan's launch of this product adds to the company's growing portfolio of more than 145 injectable products available to patients in the U.S. across a broad array of therapeutic categories including oncology, anti-infectives, anesthesia/pain management and cardiovascular.
August 24, 2015
12:57 EDTPFEFTC requires Pfizer to sell rights to four products as condition of buying Hospira
Subscribe for More Information
08:16 EDTPFEBristol-Myers, Pfizer to present new data on Eliquis at ESC Congress 2015
Bristol-Myers Squibb Company (BMY) and Pfizer Inc. (PFE) announced that 22 abstracts will be presented at the ESC Congress 2015, to be held August 29 to September 2 in London, United Kingdom. The new data reinforce the Alliance's commitment to the ongoing evaluation of Eliquis in both the nonvalvular atrial fibrillation and venous thromboembolism patient populations. In addition, data from the AEGEAN study evaluating adherence among NVAF patients further extends the Alliance's commitment to patient care.
08:01 EDTPFEPfizer receives clearance from FTC for Hospira acquisition
Subscribe for More Information
August 23, 2015
12:35 EDTPFEBiotech firms could see 'billions' in sales from new cancer drugs, Barron's says
Subscribe for More Information
August 21, 2015
08:01 EDTPFEPfizer says two Phase 3 Trumenba studies met primary endpoints
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use